PANTHERx® Rare Pharmacy Expands Services to Include Dispensing AYVAKIT® (avapritinib) for the Expanded Approval for Treatment of Indolent Systemic Mastocytosis (ISM)
June 19, 2023 PITTSBURGH – Blueprint Medicines recently announced the approval of AYVAKIT® (avapritinib) for the expanded...
Read More
PANTHERx® Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT® (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam
June 27, 2022 PITTSBURGH – PANTHERx® Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy...
Read More
PANTHERx Rare Celebrates Fifth Patient Choice Award Win
May 4, 2022 PITTSBURGH – For a fifth time, PANTHERx® Rare has been recognized as the winner of the annual, Specialty Pharmacy...
Read More
PANTHERx® Rare Selected by Aadi Bioscience to Distribute FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for advanced malignant perivascular epithelioid cell neoplasm (PEComa)
February 24, 2022 PANTHERx® Rare announces that it has been selected by Aadi Bioscience as the exclusive U.S. pharmacy distribution...
Read More
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome
January 13, 2022 PANTHERx® Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary...
Read More
2021 Marks Milestone Fourth Patient Choice Award for PANTHERx Rare
Read the Official PANTHERx Press Release. PANTHERx Rare has again been recognized as the winner of the annual, national Specialty...
Read More